Strategic Planning Group LLC Sells 1,144 Shares of Solventum Co. (NYSE:SOLV)

Strategic Planning Group LLC lowered its stake in Solventum Co. (NYSE:SOLVFree Report) by 16.6% in the 4th quarter, according to its most recent disclosure with the SEC. The fund owned 5,762 shares of the company’s stock after selling 1,144 shares during the quarter. Strategic Planning Group LLC’s holdings in Solventum were worth $381,000 at the end of the most recent quarter.

Other institutional investors have also recently made changes to their positions in the company. Modus Advisors LLC bought a new stake in Solventum during the 4th quarter valued at $25,000. Copeland Capital Management LLC purchased a new position in shares of Solventum in the third quarter valued at about $26,000. Mather Group LLC. bought a new position in shares of Solventum during the third quarter valued at about $27,000. True Wealth Design LLC boosted its holdings in shares of Solventum by 23,550.0% during the third quarter. True Wealth Design LLC now owns 473 shares of the company’s stock worth $33,000 after purchasing an additional 471 shares during the period. Finally, NCP Inc. bought a new stake in shares of Solventum in the second quarter worth about $35,000.

Solventum Stock Performance

Shares of NYSE:SOLV opened at $74.44 on Thursday. The company has a current ratio of 1.15, a quick ratio of 0.83 and a debt-to-equity ratio of 2.45. The stock has a fifty day simple moving average of $69.87 and a two-hundred day simple moving average of $66.92. Solventum Co. has a 12-month low of $47.16 and a 12-month high of $96.05.

Solventum (NYSE:SOLVGet Free Report) last announced its quarterly earnings results on Thursday, November 7th. The company reported $1.15 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.38 by ($0.23). The company had revenue of $2.08 billion for the quarter, compared to the consensus estimate of $2.05 billion. As a group, equities research analysts expect that Solventum Co. will post 6.58 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently weighed in on SOLV shares. Piper Sandler lifted their price objective on Solventum from $71.00 to $75.00 and gave the stock a “neutral” rating in a research report on Friday, November 8th. Stifel Nicolaus started coverage on shares of Solventum in a report on Tuesday, October 8th. They issued a “buy” rating and a $82.00 price target on the stock. Morgan Stanley upped their price objective on shares of Solventum from $60.00 to $73.00 and gave the stock an “equal weight” rating in a report on Monday, November 11th. Finally, Mizuho started coverage on shares of Solventum in a research note on Wednesday, December 4th. They set a “neutral” rating and a $70.00 target price on the stock. One analyst has rated the stock with a sell rating, nine have given a hold rating and one has issued a buy rating to the company. According to MarketBeat, the stock has a consensus rating of “Hold” and an average target price of $68.29.

Get Our Latest Analysis on Solventum

Solventum Company Profile

(Free Report)

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration.

Further Reading

Want to see what other hedge funds are holding SOLV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Solventum Co. (NYSE:SOLVFree Report).

Institutional Ownership by Quarter for Solventum (NYSE:SOLV)

Receive News & Ratings for Solventum Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Solventum and related companies with MarketBeat.com's FREE daily email newsletter.